Zynerba Press Releases

26 May 20 Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

26 May 20 Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

22 May 20 Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

21 May 20 Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

11 May 20 Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

10 Apr 20 Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

10 Mar 20 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

9 Mar 20 Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting

5 Mar 20 Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference

3 Mar 20 Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population